– NEPTUNE WELLNESS SOLUTIONS STUDY ON OMEGA-3, RELEASED EXCLUSIVELY BY OXFORD PRESS –
LAVAL, QC, February 24, 2021 / PRNewswire / – Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company that focuses on natural, plant-based, sustainable, and purposeful Product-focused lifestyle brands today announced groundbreaking research into the absorption of omega-3 fish oils that form the basis of the exclusive MaxSimil® product. The study was published in the Journal of Nutrition by the Oxford University Press.
MaxSimil® is a patented omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to pre-digest omega-3 fatty acids.
The study, entitled ‘Pharmacokinetics of Additional Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl esteror triglycerides in adults in a randomized crossover study ‘- complements a growing body of research on Neptune’s patented MaxSimil® fish oils.
“This puts Neptune at the forefront of the fast-growing omega-3 ingredient market that is expected to hit the USD $ 8.5 Billions by 2025, “said Michael Cammarata, Chief Executive Officer and President of Neptune. “These results confirm Neptune’s mission to disrupt consumer habits through the use of innovative ingredients like MaxSimil®, and we will continue to conduct research and studies to find out how best to introduce them into consumers’ everyday lives.”
The aim of the study was to compare the 24 hour area under the curve (AUC) of plasma concentrations of EPA, DHA and EPA + DHA when provided in monoglycerides (MAGs), ethyl esters (EEs), or triglycerides (esterified) were TGs) (primary outcomes) and assess their side effects over 24 hours (secondary outcomes).
For this study, the study was a randomized, triple-blind, controlled, crossover clinical study. Eleven women and eleven men between 18 and 50 years of age took a single oral dose of 1.2 g EPA and DHA in random order, which were esterified in MAGs, EEs and TGs with low-fat meals that were administered during the following 24 hours – above .
Eleven blood samples were taken from each participant over 24 hours and the plasma n-3 fatty acids (FAs) were quantified. Friedman’s paired ANOVA statistical rank test was used for pharmacokinetic parameters and a chi-square statistical test was used for side effects.
The report showed that the maximum EPA plasma concentration (Cmax) was 3.5 and 1.3 times higher in the MAG form, respectively, than in the EE and TG form (P = 0.0003, P < 0.0001), which indicates the higher absorption capacity compared to standard fish oil. The effects of the EE and TG treatments did not differ. The MAG form has been shown to be as safe as the EE and TG forms, with minimal reported side effects.
“This suggests that MaxSimil® fish oils bypass the early stages of digestion by providing easily absorbable forms of fats that can be absorbed directly into the intestinal tract,” he said Cedrick Billequey, General Manager of the Neptune subsidiary Biodroga Nutraceuticals. “MaxSimil®’s monoglyceride fatty acids are also absorbed without digestive enzymes. This makes MaxSimil® a great solution for those who suffer from digestive problems due to health problems, medication or age.”
The study was written by Laurie Chevalier, Annick Vachon and Dr. Mélanie Plourde from the university Sherbrooke in Québec, with their research supported and reviewed by Neptune Wellness Solutions Inc., Ingenutra, and SCF Pharma.
This study was registered at www.clinicaltrials.gov as NCT03897660.
Click here to read the full report. To read the abstract, click here.
For more information on Neptune Wellness Solutions Inc. and MaxSimil®, please visit www.neptunecorp.com.
ABOUT NEPTUNE WELLNESS SOLUTIONS INC .:
Neptune Wellness Solutions is a globally unique health and wellness company that is transforming consumer habits by creating and distributing environmentally friendly, ethical and innovative consumer products. Neptune’s simultaneous focus on customer-centric brand development in B2C and B2B provides the company with international reach and scalability from its own and operated facilities that extract and create product formulations to retail spaces at leading global retailers.
Neptune’s diversified and fully integrated business model focuses on natural, herbal, sustainable and purpose-built lifestyle brands, as well as the use of cannabinoids in household products to make them safer, healthier and more effective. The portfolio includes emerging brands such as Forest Remedies ™, Ocean Remedies ™, Neptune Wellness ™, Mood Ring ™ and OCEANO3 ™, which are geared towards rapid growth and expansion.
With a cost-effective manufacturing and supply chain infrastructure that can be scaled up and down or broken down into adjacent product categories to identify new innovation opportunities, Neptune quickly adapts to consumer preferences and demand, bringing up its products as well as other Fortune 100 brands Promote the market through strategic distribution partnerships, mass retail partners, and e-commerce channels. Neptune is committed to its core mission of redefining health and wellbeing and helping humanity thrive through sustainable consumer-centric solutions. Further information is available at: www.neptunecorp.com
Statements in this press release that are not historical or current fact constitute “forward-looking statements” within the meaning of the United States securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that may lead to them that Neptun’s actual results may differ materially from historical results or future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are encouraged to consider statements that include the terms “believes”, “believes”, “expects”, “intends”, “projects”, “anticipates”, ” will be marked “. “should” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary note and the “Forward-Looking Information Warning” section of Neptune’s most recent annual information form (the “AIF”), which is also part of Neptun’s most recent annual report on Form 40-F , which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml, and in the investor section of the Neptune website at www.neptunecorp.com. All forward-looking statements in this press release speak as of the date of this press release. Neptune undertakes no obligation to update such forward-looking statements as a result of new information, future events, or otherwise, except as required by law. The forward-looking statements contained herein include, without limitation, statements about the fulfillment of orders, the availability of products from Neptune’s supplier and the anticipated use of the funding proceeds, as well as other risks and uncertainties described from time to time in the filing of Neptune public securities with the Securities and Exchange Commission and the Canadian Securities Commissions. Further information on these assumptions as well as risks and uncertainties can be found in the AIF under “Risk Factors”.
Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Neptune Wellness Solutions Inc.